ArticleMolecular biotechnology2012
The peptide derived from erbB2 auto-inhibitor herstatin shared in the same epitope and function with functional antibody 2C4.
Article in Molecular biotechnology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 2 citations in OpenAlex.
- Soluble isoforms of EGFR family in breast cancer: Advances and clinical relevance (Review).Oncology letters · 2026Review
- Intron-Encoded Domain of Herstatin, An Autoinhibitor of Human Epidermal Growth Factor Receptors, Is Intrinsically Disordered.Frontiers in molecular biosciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Previous studies have shown that different epitopes of HER2 exhibit distinct functions and that the epitope bound by the antibody 2C4 plays a role in formation of hetereodimers between HER2 and other receptors of the HER family. In this study, we used computer modeling to determine that the epitope of HER2 which the C-terminal 79 amino acids of herstatin (named HSTC79) binds is similar to that bound by 2C4. Based on these theoretical results, recombinant HSTC79 fused with GST was expressed in Escherichia coli and purified by affinity chromatography. Experimental analysis showed that HSTC79 did specifically bind to HER2 and that the epitope of HER2 identified by HSTC79 was near that identified by 2C4. Furthermore, HSTC79 inhibited the growth of HER2-overexpressing cells. These results highlight the fact that the binding site architecture and certain key residues of HER2 may be very helpful for understanding the protein's biological role and providing insights for designing novel inhibitors of HER2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.